Welcome to our dedicated page for Quest Diagnostics news (Ticker: DGX), a resource for investors and traders seeking the latest updates and insights on Quest Diagnostics stock.
Quest Diagnostics Incorporated reports developments in diagnostic information services, laboratory testing and related healthcare data offerings. Company news commonly covers financial results, guidance, clinical testing activity, consumer access through questhealth.com and MyQuest, and advanced diagnostics such as Quest AD-Detect blood tests for Alzheimer’s disease and Haystack MRD ctDNA testing for oncology research.
Updates also include health system collaborations, Co-Lab Solutions activity, clinical trial and research partnerships, AI-enabled patient tools, board and executive appointments, dividends, share repurchases, debt financing and shareholder voting matters.
Quest Diagnostics (NYSE: DGX) will report fourth quarter and full year 2025 financial results on Tuesday, February 10, 2026 before market open. The company will host a conference call at 8:30 a.m. Eastern Time the same day.
Dial-in details: 888-455-0391 (U.S./Canada) or 773-756-0467 (international) with passcode 7895081. The earnings release and live webcast will be posted at www.QuestDiagnostics.com/investor. Participants are advised to dial in ~10 minutes early.
A replay will be available online at the investor site and by phone at 866-388-5361 (domestic) or 203-369-0416 (international) from ~10:30 a.m. ET on February 10, 2026 until midnight ET on February 24, 2026. Investors are encouraged to review the company’s periodic SEC filings, including risk factors.
Quest Diagnostics (NYSE: DGX) announced that data using its Haystack MRD® circulating tumor DNA test will be presented at the 2026 ASCO Gastrointestinal Cancers Symposium, held January 8-10, 2026 in San Francisco and online.
Two poster presentations on January 10, 2026 (12:00 PM–1:30 PM PST) will report: 1) reproducibility and clinical concordance of a tumor-informed MRD assay in resected colorectal cancer from the DYNAMIC trials (Abstract 26; lead author Jeanne Tie) and 2) use of ctDNA to monitor patients undergoing total neoadjuvant treatment for locally advanced rectal adenocarcinoma (Abstract 30; lead author Eric Christenson).
Corewell Health and Quest Diagnostics (NYSE: DGX) completed a joint venture to form Diagnostic Lab of Michigan, LLC, with Quest owning 51% and Corewell owning 49%. The JV will expand access to laboratory services in Michigan and operate while existing labs continue to serve patients until a new 100,000-square-foot laboratory at Corewell Health Southfield Center opens in Q1 2027.
Quest has begun deploying its Collaborative Lab Solutions (Co-Lab) across all 21 Corewell hospitals, including supply chain, lab management, patient blood and anemia management, lab analytics and stewardship, and reference testing to support quality, innovation, access and productivity.
Quest Diagnostics (NYSE: DGX) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 12, 2026 at 4:30 p.m. PT. Jim Davis, Chairman, CEO and President, and Sam Samad, EVP and CFO, will discuss the company’s strategy, performance, and market trends during a presentation and Q&A.
The session will be webcast live and available at ir.QuestDiagnostics.com; an archived webcast will be posted within 24 hours and will remain available through February 11, 2026.
Haystack Oncology (Quest Diagnostics NYSE: DGX) announced a research collaboration with Rutgers Cancer Institute and RWJBarnabas Health to evaluate Haystack MRD, a circulating tumor DNA (ctDNA) test, in a prospective phase II trial titled MRD-PORT (NCT06979661) to guide postoperative radiation and systemic therapy in stage II/III non-small cell lung cancer.
Key context: an April 2025 NEJM study found Haystack MRD identified clinical complete response at a median of 1.4 months vs >6 months by imaging, and the test received FDA Breakthrough Device Designation in August 2025.
Octave Bioscience announced a strategic collaboration with Quest Diagnostics (NYSE: DGX) to make the Octave® Multiple Sclerosis Disease Activity (MSDA) Test available through Quest’s approximately 7,000 U.S. patient service centers and in-office phlebotomists starting December 1, 2025.
The MSDA Test measures 18 validated protein biomarkers, is described as clinically and analytically validated, is reimbursed by multiple payers, and is supported by a patient affordability program. Quest also has first rights to consider providing specimen collection for future Octave tests. The MSDA Test is performed in Octave’s CLIA/CAP/CLEP-certified Menlo Park laboratory.
Summary not available.
Quest Diagnostics (NYSE: DGX) announced that its Board declared a quarterly cash dividend of $0.80 per share. The dividend is payable on January 28, 2026 to shareholders of record as of January 13, 2026. This provides a scheduled cash return to common shareholders and sets the key dates for eligibility and payment.
Quest Diagnostics (NYSE: DGX) announced that Sam Samad, executive vice president and chief financial officer, will speak at Citi's 2025 Global Healthcare Conference in Miami on Tuesday, December 2, 2025 at 3:15 p.m. ET.
The session will be a fireside chat with Q&A and will be webcast live on the company's investor relations page at ir.QuestDiagnostics.com. An archived webcast will be posted within 24 hours and will remain available through January 2, 2026.
Quest Diagnostics (NYSE: DGX) published a study showing two AD-Detect blood-test panels accurately identify Alzheimer’s pathology in symptomatic patients. In an intended-use cohort of 215 patients (46% amyloid PET-positive), both panels met a 91% sensitivity and 91% specificity threshold used for confirmatory testing. The three-biomarker panel (AB42/40 + p-tau217 + ApoE4) yielded PPV 88%, NPV 91% and a 10% indeterminate rate. The two-biomarker panel (AB42/40 + p-tau217) showed PPV 87%, NPV 91% and a 15% indeterminate rate. Quest launched the two-biomarker panel in April 2025 and plans a version of the three-biomarker test in Q1 2026.
Results meet recommended thresholds from Alzheimer's Association and CEOi for confirmatory blood-based tests, suggesting potential to reduce reliance on PET or CSF follow-up.